A multi-institutional phase 2 trial of regorafenib in refractory advanced biliary tract cancer.

ABSTRACT:

Background

Regorafenib is an oral multikinase inhibitor targeting angiogenesis, oncogenesis, and cancer proliferation/metastasis. This study evaluated the efficacy of regorafenib in refractory biliary tract cancer (BTC) in a multi-institutional phase 2 study.

Methods

Patients with BTC who progressed on at least 1 line of systemic therapy received regorafenib at 160 mg daily for 21 days on and 7 days off. The primary endpoint was 6-month overall survival (OS), and the secondary endpoints were median OS, progression-free survival (PFS), and objective response rates. Pretreatment plasma was collected for cytokine evaluation.

Results

A total of 39 patients were enrolled, and 33 were evaluable for efficacy. The median PFS and OS were 3.7 and 5.4 months, respectively, with

SUBMITTER: Kim RD 

PROVIDER: S-EPMC7787270 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature